NEOG vs PACB Stock Comparison

NEOG currently leads PACB in this stock comparison, with AIQ scores of 63 vs 48. The clearest difference is risk resilience, while PACB has the stronger momentum profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 15 points
NEOG
Healthcare
vs
PACB
Healthcare
NEOG
Neogen Corporation
Leads
Price
$11.08
Day move
+1.65%
AIQ Score
63/100
Best edge
Risk Resilience
Sector
Healthcare
PACB
Pacific Biosciences of California, Inc.
Price
$1.83
Day move
+0.55%
AIQ Score
48/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between NEOG and PACB?

NEOG leads the current stock comparison as Neogen Corporation, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Neogen Corporation vs Pacific Biosciences of California, Inc.

Data as of Nov 18, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 7/10

NEOG leads

NEOG leads by 15 AIQ points, primarily on Risk Resilience and Quality, but the lead has narrowed from 22 points over 30 sessions.

Competitive: 4 of 6 evidence groups support NEOG, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 4 of 6Comparison trend: Weakening
NEOG

Neogen Corporation

Leads
AIQ Score
63/100
AIQ Edge Score
7/10
PACB

Pacific Biosciences of California, Inc.

AIQ Score
48/100
AIQ Edge Score
4/10

The Algovestiq AIQ Score currently favors NEOG over PACB, 63 versus 48 as of Nov 18, 2026. NEOG's advantage is driven primarily by stronger risk resilience and quality, while PACB holds the stronger momentum profile. NEOG also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor NEOG today, and the comparison is rated Competitive on stability: the leader's advantage has been narrowing. NEOG lead: Weakening — the AIQ differential moved from 22 to 15 points over 30 sessions.

Compare Neogen Corporation and Pacific Biosciences of California, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

NEOG
-74.9%
PACB
-91.9%

Price return comparison

Growth of $10,000, price only

NEOG $2,512 · PACB $807

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare NEOG and PACB against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

NEOG advantage
0
PACB advantage
  • Risk Resilience57 vs 24
    NEOG +33
  • Quality63 vs 32
    NEOG +31
  • Value49 vs 23
    NEOG +26
  • Momentum74 vs 84
    PACB +10

4 of 6 evidence groups favor NEOG. NEOG’s edge is concentrated in risk resilience and quality; PACB keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

NEOG-1 AIQ

Largest factor move: Value -1

New signals

  • OBV Bullish Divergence — bullish, volume, medium horizon (-4.9%)
  • RSI Bullish Divergence — bullish, momentum, medium horizon
  • Stochastic Oversold Bounce — bullish, momentum, short horizon
PACB0 AIQ

Largest factor move: Value -1, not enough on its own to move the overall score.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
  • Stochastic Oversold Bounce — bullish, momentum, short horizon

NEOG's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — NEOG and PACB both carry a full feed there.

The central trade-off

NEOG (Neogen Corporation): the stronger current systematic profile, led by risk resilience and quality.

PACB (Pacific Biosciences of California, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 114.1% against 40%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

NEOG

NEOG on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

PACB

PACB on combined revenue and EPS growth.

Value

NEOG

NEOG on the peer-relative Value factor, by 26 points.

Momentum

PACB

PACB on the Momentum factor, by 10 points.

Lower downside

NEOG

NEOG on Risk Resilience, by 33 points.

Analyst upside

NEOG

NEOG on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureNEOGPACBNote
Implied upside to target+26.4%+5.2%NEOG has more room
Target dispersion0%+59.7%Lower is tighter analyst agreement
ConsensusBuyHoldContext, not a primary driver
Analysts covering48Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 6 covered evidence groups favor NEOG. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreNEOG63 vs 48
FundamentalsEvenrevenue growth -1.1% vs 4%; gross margin 47.4% vs 34.5%
ValuationNEOGValue 49 vs 23
TechnicalsPACBPrice vs 50-day -9.5% vs -8.7%; vs 200-day 6.8% vs 22.4%
Risk ResilienceNEOGRisk Resilience 57 vs 24
Analyst expectationsNEOGTarget upside 26.4% vs 5.2%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of NEOG and PACB and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 15 points. (supports the conclusion holding)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on NEOG.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

NEOG lead: Weakening — the AIQ differential moved from 22 to 15 points over 30 sessions.

Jun 1NEOG leads above the line · PACB leads belowNov 18
Today
NEOG +15
63 vs 48
7 sessions ago
NEOG +16
65 vs 49
30 sessions ago
NEOG +22
66 vs 44
90 sessions ago
NEOG +33
63 vs 30

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

NEOGConflicted

4 bullish / 1 bearish / 1 neutral, conflicted

Only NEOG

  • OBV Bullish Divergence — bullish, volume, medium horizon (-4.9%)
  • RSI Bullish Divergence — bullish, momentum, medium horizon
PACBConflicted

3 bullish / 3 bearish / 1 neutral, conflicted

Only PACB

  • Beta Spike Warning — bearish, risk_regime, long horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)

Both carry 4 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, MACD Histogram Expanding Bearish, Stochastic Oversold Bounce.

NEOG leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

NEOGDivergence

Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +1.65%, AIQ -1 points).

PACBNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1PACB closes the Risk Resilience gap — currently 33 points behind, the largest single contributor to NEOG's edge.
  2. 2PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3NEOG's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 15-point move would eliminate NEOG's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

Split
MetricNEOGPACB
Revenue growth (YoY)-1.1%4%
EPS growth (YoY)0%14.3%
Gross margin47.4%34.5%
Operating margin-0.8%-99.6%
Return on equity (TTM)-0.6%61.7%
Debt to equity0.37-11.49

Performance

Split across windows
MetricNEOGPACB
1 week (5 sessions)-4.5%-13.1%
1 month (20 sessions)-4.9%13.3%
3 months (63 sessions)-5.4%62%
6 months (126 sessions)37.1%75%
Year to date60.7%4.8%
1 year (252 sessions)73.6%12.6%

Technicals

PACB has the stronger structure
MetricNEOGPACB
RSI (14)40.143.1
ADX (14)13.427.4
Price vs 50-day-9.5%-8.7%
Price vs 200-day6.8%22.4%
Volatility (1M, annualized)40%114.1%

Risk

NEOG is the more resilient
MetricNEOGPACB
Beta1.412.1
Sharpe ratio1.190.61
Sortino ratio2.240.96
Max drawdown-27.7%-58.4%
Current drawdown-19.7%-32.4%
Annualized volatility57.9%93.5%
Value at risk (95%)-4.4%-9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, NEOG or PACB?

On the Algovestiq AIQ Score, NEOG is the stronger of the two as of Nov 18, 2026, scoring 63 against PACB's 48. The edge comes from risk resilience and quality. PACB is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is NEOG or PACB the better buy right now?

NEOG carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor NEOG over PACB?

The composite weights Quality, Value, Momentum and Risk Resilience. NEOG leads Risk Resilience by 33 points; NEOG leads Quality by 31 points; NEOG leads Value by 26 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, NEOG or PACB?

Analyst price targets imply +26.4% upside for NEOG and +5.2% for PACB, so the Street currently favors NEOG. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, NEOG or PACB?

NEOG is the better-valued of the two on the peer-relative Value factor. NEOG on the peer-relative Value factor, by 26 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, NEOG or PACB?

PACB on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, NEOG or PACB?

PACB on the Momentum factor, by 10 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, NEOG or PACB?

NEOG is the more resilient of the two, so the other name carries the higher downside risk. NEOG on Risk Resilience, by 33 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is NEOG more profitable than PACB?

NEOG leads on the comparable margin measures — gross margin 47.4% vs 34.5%; operating margin -0.8% vs -99.6%; ttm roe -0.6% vs 61.7%.

Is NEOG's lead over PACB getting stronger or weaker?

NEOG lead: Weakening — the AIQ differential moved from 22 to 15 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.

What would change the NEOG vs PACB verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PACB closes the Risk Resilience gap — currently 33 points behind, the largest single contributor to NEOG's edge; PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; NEOG's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 15-point move would eliminate NEOG's advantage entirely.

What do the current signals say about NEOG and PACB?

NEOG: 4 bullish / 1 bearish / 1 neutral, conflicted. PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on NEOG is Golden Cross Active (bullish, long horizon). On PACB it is Golden Cross Active (bullish, long horizon).

Compare NEOG and PACB with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.